Literature DB >> 18757786

Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.

Gezim Lahu1, Andreas Huennemeyer, Oliver von Richter, Robert Hermann, Rolf Herzog, Nigel McCracken, Karl Zech.   

Abstract

Effects of single and multiple doses of oral ketoconazole on roflumilast and its active metabolite, roflumilast N-oxide, were investigated in healthy subjects. In study 1, subjects (n = 26) received oral roflumilast 500 microg once daily for 11 days and a concomitant 200-mg single dose of ketoconazole on day 11. In study 2, subjects (n = 16) received oral roflumilast 500 microg on days 1 and 11 and a repeated dose of ketoconazole 200 mg twice daily from days 8 to 20. Coadministration of single-dose ketoconazole with steady-state roflumilast increased the AUC of roflumilast by 34%; C(max) was unchanged. For roflumilast N-oxide, AUC and C(max) decreased by 12% and 20%, respectively. Repeated doses of ketoconazole increased the AUC and C(max) of roflumilast by 99% and 23%, respectively; for roflumilast N-oxide, AUC was unchanged, and C(max) decreased by 38%. No clinically relevant adverse events were observed. Coadministration of ketoconazole and roflumilast does not require dose adjustment of roflumilast.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18757786     DOI: 10.1177/0091270008321941

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  6 in total

1.  Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

Authors:  Jordan Baye
Journal:  P T       Date:  2012-03

Review 2.  Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

Authors:  Klaus F Rabe
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

3.  Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

Authors:  Gezim Lahu; Andreas Hünnemeyer; Edgar Diletti; Martin Elmlinger; Peter Ruth; Karl Zech; Nigel McCracken; Axel Facius
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

Review 4.  Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Authors:  Mark A Giembycz; Stephen K Field
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

5.  Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.

Authors:  Nassr Nassr; Andreas Huennemeyer; Rolf Herzog; Oliver von Richter; Robert Hermann; Manuela Koch; Kevin Duffy; Karl Zech; Gezim Lahu
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

6.  No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.

Authors:  Christian de Mey; Nassr Nassr; Gezim Lahu
Journal:  BMC Clin Pharmacol       Date:  2011-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.